Patients with type 2 diabetes who initiated canagliflozin treatment had a lower rate of heart failure events and a lower risk for hospital admissions for acute myocardial infarction, heart failure, hemorrhagic stroke or ischemic stroke, compared with those who received a DPP-4 inhibitor, sulfonylurea or GLP-1 receptor agonist, according to a study in The BMJ. Researchers used a cohort of 55,560 adult diabetes patients and found that the canagliflozin group had a lower number of composite cardiovascular endpoint events than the DPP-4 inhibitor and sulfonylurea groups, but had a higher rate than the GLP-1 receptor agonist group.
Researchers compare CV outcomes among different diabetes drugs
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.